Research Grants

Research Grants


Every year, the Sandy Rollman Ovarian Cancer Foundation, Inc. funds research to find a cure for ovarian cancer, a screening test for early detection, breakthrough treatments and improve the quality of life for those living with ovarian cancer. Special consideration is given to those researchers in the state of Pennsylvania. However, we welcome submissions from all cutting edge ovarian cancer researchers.


Research proposals may be individual projects or part of a larger research project related to ovarian cancer. All research proposals will be considered, however, special consideration will be given to local research projects. Consideration will be given to proposals leading to early detection, better treatment or a cure for ovarian cancer.

Grant proposals for 2020 may not exceed $50,000.


Recommendation of award recipients will be made by Board Members and/or a member of the Medical Advisory Board. Proposals will be reviewed by a member of our Medical Advisory Board. The recommended will be discussed and voted on by Board Members.

Time Line

Research Grant Submissions are on HOLD due to the Coronavirus. We will update you when submissions resume. Notification of action by the Sandy Rollman Ovarian Cancer Foundation, Inc. will be given within 30 days of receipt of the proposal.

Application Requirements

Proposals must include the following:

  1. Abstract of proposed research rationale of the study, aims, and an overview of research design and methods.
  2. Summary of proposed research proposal (one paragraph) which describes the proposed research in terms an educated lay person would understand and describes the significance of the research to the patient population.
  3. Research Proposal (not to exceed 6 pages- not including references) Include any supporting information deemed essential.
  4. Budget detailing direct cost expenditures. All costs must be itemized. Sandy Rollman Ovarian Cancer Foundation, Inc. funds cannot be used for indirect costs, PI salary replacement, or travel.Information about PI should include:
    • Statement of career goals of PI- (one page).
    • Curriculum vitae-including education, honors, professional experience, publications, grants.
    • Contact information for PI which includes direct phone number and email
  5. Letter of recommendation from the relevant person overseeing institution, department or lab where the research will be conducted.
  6. Project Timeline detailing the expected chronological progress of research goals.

Proposals are due to the SROCF office by TBA

Send one orignial hard copy of the proposal to:

Robin CohenExecutive DirectorSandy Rollman Ovarian Cancer Foundation 308 E Lancaster Avenue, Suite 225 , Wynnewood, PA 19096

Additonally, send an electronnic version of the proposal with attachments to Robin Cohen at


2019 Grants:
Dr. Timothy Yen at Fox Chase Cancer Center
Dr. Katherine Aird at Hershey Medical Center
American Cancer Society Grant

2018 Grants:
Stand Up to Cancer Ovarian Cancer Dream Team Grant
Dr. James Duncan at Fox Chase Cancer Center
OCRA Research Grant

2017 Grants:
Stand Up to Cancer Ovarian Cancer Dream Team Grant
Dr. Neil Johnson at Fox Chase Cancer Center

2016 Grants:

Stand Up to Cancer Ovarian Cancer Dream Team Grant

$50,000 to Dr. Garcia at University of Pennsylvania

2015 Grants:

Stand Up to Cancer Ovarian Cancer Dream Team Grant

$30,000 to Dr. Paul Cairns at Fox Chase Cancer Center

2014 Grants:

Stand Up to Cancer Ovarian Cancer Dream Team Grant

$50,000 to Dr.Kasia Urbanska at the University of Pennsylvania

2013 Grants:

$50,000 to Drs. George Coukos, MD, Ph.D. and Chunsheng Li, Ph.D. at Penn Ovarian Cancer Research Center for Bi-specific T-cell Engagers (BiTEs) against tumor vasculature as an immune therapy for ovarian cancer.

$50,000 to Erica Golemis, Ph.D. at Fox Chase Cancer Center for Therapeutic targeting of ovarian cancer with HSP90 inhibitor ganetespib (STA-9090).

$50,000 to Sandra Orsulic, Ph.D. in collaboration with Beth Karlan, MD at Cedars-Sinai Medical Center for A Discriminatory Gene Signature for Early Ovarian Cancer Recurrence.